Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 558

1.

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association.

Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS; American Diabetes Association; American College of Cardiology Foundation; American Heart Association.

J Am Coll Cardiol. 2009 Jan 20;53(3):298-304. doi: 10.1016/j.jacc.2008.10.008. Review. No abstract available.

2.

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association.

Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS; American Diabetes Association; American College of Cardiology Foundation; American Heart Association.

Circulation. 2009 Jan 20;119(2):351-7. doi: 10.1161/CIRCULATIONAHA.108.191305. Epub 2008 Dec 17. No abstract available. Erratum in: Circulation. 2009 Jun 30;119(25):e605.

3.

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association.

Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS; American Diabetes Association; American College of Cardiology Foundation; American Heart Association.

Diabetes Care. 2009 Jan;32(1):187-92. doi: 10.2337/dc08-9026. Epub 2008 Dec 17. No abstract available. Erratum in: Diabetes Care. 2009 Apr;32(4):754.

5.

[Intensive glycemia control of type-2 diabetes mellitus: a real A(D)VANCe or a deep dis(ACCORD)?].

Lambiel J, Fumeaux T.

Rev Med Suisse. 2008 Aug 6;4(166):1734. French. No abstract available.

PMID:
18777740
7.

Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials.

Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N.

Nutr Metab Cardiovasc Dis. 2009 Nov;19(9):604-12. doi: 10.1016/j.numecd.2009.03.021. Epub 2009 May 8.

PMID:
19427768
8.

Implications of intensive glycemic control on cardiovascular disease: early reports from the ACCORD and ADVANCE Trials.

Soo Yeon S, Nesto RW.

Rev Cardiovasc Med. 2008 Winter;9(1):1-4. Review. No abstract available.

PMID:
18418304
9.

ACCORD and ADVANCE: a tale of two studies on the merits of glycaemic control in type 2 diabetic patients.

Karalliedde J, Gnudi L.

Nephrol Dial Transplant. 2008 Jun;23(6):1796-8. doi: 10.1093/ndt/gfn200. Epub 2008 Apr 10. No abstract available.

PMID:
18403430
10.

Should you put all diabetic patients on statins?

Leiter LA.

J Fam Pract. 2007 Apr;56(4):294-300. Review. No abstract available.

PMID:
17403328
11.

[Intensive glucose control in type 2 diabetes is beneficial].

Nilsson PM, Attvall S.

Lakartidningen. 2009 Sep 2-8;106(36):2198. Swedish. No abstract available.

PMID:
19817174
12.

[ACCORD (Action to Control Cardiovascular Risk in Diabetes trial) becoming "two-tone"].

Seufert J.

Dtsch Med Wochenschr. 2008 May;133(20):1068-70. doi: 10.1055/s-2008-1077219. German. No abstract available.

PMID:
18461525
13.

Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials.

Stettler C, Allemann S, Jüni P, Cull CA, Holman RR, Egger M, Krähenbühl S, Diem P.

Am Heart J. 2006 Jul;152(1):27-38. Review.

PMID:
16824829
14.
15.

Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association.

Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ; American Heart Association; American Diabetes Association.

Diabetes Care. 2007 Jan;30(1):162-72. Review.

PMID:
17192355
16.

How to ADVANCE prevention of cardiovascular complications in type 2 diabetes.

Grobbee DE.

Metabolism. 2003 Aug;52(8 Suppl 1):24-8. Review.

PMID:
12939736
17.

Effect of intensive glycemic control on cardiovascular outcomes and all-cause mortality in type 2 diabetes: Overview and metaanalysis of five trials.

Tkác I.

Diabetes Res Clin Pract. 2009 Dec;86 Suppl 1:S57-62. doi: 10.1016/S0168-8227(09)70011-7.

PMID:
20115934
18.

Implications of the diabetes control and complications trial. American Diabetes Association.

[No authors listed]

J Fla Med Assoc. 1998 Aug;85(2):22-4. No abstract available.

PMID:
9782715
19.

[Intensive blood sugar treatment in type 2 diabetics: no evidence for increased mortality in the ADVANCE study compared with ACCORD study].

Füchtenbusch M, Hummel M.

MMW Fortschr Med. 2008 Apr 24;150(17):42-4. German. No abstract available.

PMID:
18510157
20.

Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation.

Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL; American Diabetes Association; American College of Cardiology Foundation.

Diabetes Care. 2008 Apr;31(4):811-22. doi: 10.2337/dc08-9018. Review. No abstract available.

PMID:
18375431

Supplemental Content

Support Center